Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (499)	11/3/2005 2:59:16 PM
From: RealMuLan	Read Replies (1) \| Respond to of 590

From Briefing.com news update finance.messages.yahoo.com 14:30 IMCL Imclone: Further color on panitumumab data (28.64 -7.47) -Update- Rodman and Renshaw notes that AMGN and ABGX announced that a Phase III study of panitumumab met its primary endpoint of improving progression free survival in third-line metastatic colorectal cancer patients. They believe that panitumumab is unlikely to be materially superior to IMCL's Erbitux, and that today's dramatic sell-off of IMCL is an over-reaction. They note that response rates for panitumumab and Erbitux have generally hovered around 10%, with the only major differentiator to date being the ~3 month progression free survival for panitumumab presented at ASCO 2005. They say that nothing in today's data suggested that panitumumab's PFS will be significantly better than Erbitux's.